NCT00000391View on ClinicalTrials.gov

A Phase I Trial of Intranasal Peptide T: Safety, Toxicity, and Pharmacokinetics in Human Immunodeficiency Virus-1 (HIV-1) Infected Patients.

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 31, 1988

Primary Completion Date

January 31, 1990

Conditions
HIV Infections
Interventions
DRUG

Peptide T

Trial Locations (1)

Unknown

Fenway Clinic, Boston

All Listed Sponsors
lead

National Institute of Mental Health (NIMH)

NIH

NCT00000391 - A Phase I Trial of Intranasal Peptide T: Safety, Toxicity, and Pharmacokinetics in Human Immunodeficiency Virus-1 (HIV-1) Infected Patients. | Biotech Hunter | Biotech Hunter